U$6.5 billion Buy, Bye of Momenta after it created Momentum | SVA.V Message Board Posts

SVA.V   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  684 of 733  at  9/17/2020 12:56:20 AM  by

jwallisca

The following message was updated on 9/17/2020 1:02:48 AM.

U$6.5 billion Buy, Bye of Momenta after it created Momentum

U$6.5 Billion is only money... but publicity created the Momentum.
n.b. I suspect Sernova will be doing that at Virtual Mesa mid-October per a previous post.
 
Excerpt:
 
As for SVA, today's news and the weak general markets worked at cross purposes... but so goes September (and October). That said, the news was really all about a corporate update for Sernova if the details were understood enough. The SVA markets have been starved for information. Looks like Sernova's longtime buddy, ViaCyte, will Virtually run the show.
 
News Body:

Sernova to also present Corporate Update as part of Company Presentations

London, Ontario - TheNewswire - September 10, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine company, announced today that Dr. Philip Toleikis, President and CEO, will be a member of the Cell and Gene Therapies for Chronic Conditions panel at the virtual 2020 Cell & Gene Meeting on the Mesa. The panel session will be available on-demand to attendees as of Thursday, October 15, 2020. Dr. Toleikis will also provide an update on Sernova's clinical and research programs as part of the 2020 Company Presentations segment of the conference.

The panel will discuss the latest developments in Cell and Gene therapies for chronic conditions and will be moderated by Paul Laikind, Ph.D., President, and CEO of ViaCyte, Inc. In addition to Drs. Toleikis and Laikind, panelists are Pavan Cheruvu, M.D., CEO, Axovant Gene Therapies; Jane Lebkowski, Ph.D., President of R&D, Regenerative Patch Technologies, Inc.; and Emile Nuwaysir, Ph.D., President and CEO, BlueRock Therapeutics.

The panel will also participate in one of only two daily Live Streaming Sessions with Questions and Answers from participants on October 13, 2020 from 12:00 - 1:00pm PST.

Sernova's Corporate Update presentation will be available on-demand to attendees of the Virtual Cell & Gene Meeting on the Mesa throughout the conference. For more details on the panel and Sernova's presentation, please visit www.meetingonthemesa.com .

https://www.fiercebiotech.com/biotech/j-j-free-from-rival-bidders-made-momenta-wait-6-5b-deal

Excerpt:
Discussions continued into 2020, when J&J floated the possibility of putting a proposal to Momenta ahead of the delivery of data from a phase 2 trial of the asset at the center of the talks, nipocalimab. J&J missed that deadline but moved quickly after seeing the top-line data, submitting a nonbinding buyout offer of $50 a share a week after Momenta publicly disclosed the results.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 42
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






Financial Market Data provided by
.
Loading...